慧宝源HEBABIZ品牌怎么样 申请店铺

我要投票 慧宝源HEBABIZ在医疗器械行业中的票数:169 更新时间:2025-04-04
慧宝源HEBABIZ是哪个国家的品牌?「慧宝源HEBABIZ」是 广西慧宝源健康产业有限公司 旗下著名品牌。该品牌发源于广西钦州市,由创始人詹姆 * ·周在2013年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力慧宝源HEBABIZ品牌出海!通过在本页面挂载慧宝源HEBABIZ品牌的产品链接和联系邮箱,可以提高慧宝源HEBABIZ产品曝光!跨境电商爆单神器,目前只要100元/年哦~

慧宝源HEBABIZ怎么样

广西慧宝源医药科技有限公司(以下称慧宝源)由国家”科技创新创业人才”入选者、美国耶鲁大学归国学者于2013年创建,设在钦州产业园,占地约470亩,注册资金2亿元。

企业专注于抗肿瘤和肝病药物研究开发,专注于提升中药质量标准,生产供应高品质中成药,努力推动传统中药走向世界。

慧宝源拥有目前有90个药品批文,180多项国际国内授权专利,已建成1个抗肿瘤药物研究中心、3个技术中心、1个院士工作站、1个博士后创新基地以及68000平米高品质的中成药生产基地。规划在建的化药生产基地与中成药生产基地相互呼应,中国—马来西亚钦州产业园区管理委员会和慧宝源一起打造的一个公共创新服务平台,为同是医药行业的合作伙伴提供创新药物研发、生产、销售一体化的服务。

公司产品线丰富,涵盖:肠胃、呼吸、肝胆、皮肤、心脑血管、神经、口腔、伤痛等品类;既有口服制剂系列,还有药酒系列和外用制剂系列。另外,公司还生产中药细粉、功能食品等产品。

慧宝源充分利用国际国内两大市场,在国内建立了广泛的产品销售网络,与国药控股、上药集团、华润控投、九州通等全国性主流商业,以及阿里健康、康爱多、好药师等连锁大药房,建立了良好的合作关系。在国际市场,慧宝源与马来西亚较大医药进出口商海鸥集团达成了战略合作。


Guangxi huibaoyuan Pharmaceutical Technology Co., Ltd. (hereinafter referred to as huibaoyuan) was founded in 2013 by the national "science and technology innovation and entrepreneurship talents" selected and returned scholars from Yale University in the United States. It is located in Qinzhou Industrial Park, covering an area of about 470 mu, with a registered capital of 200 million yuan. The company focuses on the research and development of anti-tumor and hepatopathy drugs, focuses on improving the quality standards of traditional Chinese medicine, produces and supplies high-quality Chinese patent medicine, and strives to promote the traditional Chinese medicine to the world. At present, huibaoyuan has 90 drug approvals and more than 180 international and domestic authorized patents. It has built an anti-tumor drug research center, three technology centers, an academician workstation, a postdoctoral innovation base and a 68000 square meter high-quality Chinese patent production base. The planned chemical medicine production base and Chinese patent medicine production base echo each other. The Management Committee of China Malaysia Qinzhou Industrial Park and huibaoyuan jointly build a public innovation service platform to provide innovative medicine research and development, production and sales integration services for partners in the pharmaceutical industry. The company's product line is rich, covering: gastrointestinal, respiratory, hepatobiliary, skin, cardio cerebrovascular, nerve, oral, pain and other categories; there are not only oral preparation series, but also liquor series and external preparation series. In addition, the company also produces fine powder of traditional Chinese medicine, functional food and other products. Huibaoyuan has made full use of the two major international and domestic markets, established a wide range of product sales network in China, and established a good cooperative relationship with national mainstream businesses such as Sinopharm holdings, Shanghai Pharmaceutical Group, China Resources holding investment, Jiuzhoutong, as well as chain drugstores such as Ali health, kangaido, and haoyaoshi. In the international market, huibaoyuan has reached strategic cooperation with Haiou group, a large pharmaceutical importer and exporter in Malaysia.

本文链接: https://brand.waitui.com/1a6c5e9a3.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

美国2月贸易逆差1227亿美元

美国商务部普查局4月3日发布数据,2月贸易逆差1227亿美元,预估为逆差1235亿美元,前值为逆差1314亿美元。(界面)

2小时前

美股大型科技股盘前普跌,苹果跌超7%

36氪获悉,美股大型科技股盘前普跌,截至发稿,苹果、亚马逊跌超7%,特斯拉、Arm、英伟达跌超6%,Meta跌超5%,谷歌跌超4%,微软、奈飞跌超3%。

2小时前

热门中概股美股盘前普跌,拼多多跌超6%

36氪获悉,热门中概股美股盘前普跌,截至发稿,拼多多跌超6%,京东跌超5%,百度、爱奇艺、阿里巴巴、B站、蔚来跌超3%,理想汽车跌超2%,网易、腾讯音乐、微博跌超1%。

2小时前

高测股份:控股股东张顼拟询价转让4.99%股份

36氪获悉,高测股份公告,公司控股股东张顼计划通过询价转让方式转让27,308,000股,占公司总股本的4.99%,转让原因为自身资金需求。出让方声明所持股份权属清晰,不存在限制或禁止转让情形,且不违反相关减持规定和承诺。本次询价转让的受让方需为具备相应定价能力和风险承受能力的机构投资者。本次询价转让的价格下限不低于发送认购邀请书之日(即2025年4月3日)前20个交易日高测股份股票交易均价的70%。

2小时前

欧盟成员国拟表决对美关税反制措施

欧盟高级官员4月3日表示,欧盟成员国计划9日投票表决针对美方25%钢铝关税的反制措施。欧盟委员会负责贸易和经济安全等事务的委员马罗什·谢夫乔维奇表示,不合理的关税最终只会适得其反,欧盟将以冷静、有步骤且团结一致的方式作出回应。(新华社)

2小时前

本页详细列出关于仁和可立克的品牌信息,含品牌所属公司介绍,仁和可立克所处行业的品牌地位及优势。
咨询